Bharatbook.com announces a new report on "Global Orphan Drug Market Outlook" which has been experiencing a slow growth in recent years owing to many factors such as expiration of patents, competition from generic drugs segment, exhausting pipelines, and an increasingly stringent regulatory framework.
City-Mumbai State-Maharashtra, India., March 1, 2014 - (PressReleasePoint) -
Mar 01, 2014 : Bharat Book Bureau presents the new report, on 'Global Orphan Drug Market Outlook'. It is most likely that many blockbuster drugs would lose their exclusivity in the next 5 year horizon.
Thus, due to significant competition from generics and the current economic situation, the focus area of the pharmaceutical companies is undergoing a paradigm shift from manufacturing traditional essential medicines to investing in the new business model, which is also called orphan drugs. The returns on investment from orphan drugs are expected to help the pharma companies to overcome the impact of revenue loss due to expiry of patents of blockbuster drugs.
The major drivers for companies to increasingly invest in orphan drugs include government incentives for drug development and strong support from the FDA and EU Commission in special protocols. Inspite of pharma companies facing many obstacles in this field, this segment of orphan drugs is likely to have the potential to provide the key to recovery and stability within the market.
The orphan drugs enjoy significant competitive advantages in the market owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs.
Global & Regional Orphan Drug Market Overview
Orphan Drug Designation Criteria Across Key Markets
Market Specific Reimbursement Policy & Regulatory Framework
Orphan Drug Pipeline by Phase, Orphan Designated Disease & Country
Press Contact: sandhya nair Office No.810, Real Tech Park, 8th Floor, Plot No. 39/2, Sector-30A,Vashi, Navi Mumbai - 400703 +91 22 27810772 *******@b**r**b**k.com Email partially hidden to block spam. Please use the contact form here.
Contact sandhya nair
Email the contact person for this press release. Do not send spam or irrelevant message.